Autolus Therapeutics (AUTL) Operating Expenses (2017 - 2026)
Autolus Therapeutics' (AUTL) quarterly Operating Expenses came in at $96.8 million in Q4 2025, up 27.49% YoY from $75.9 million in Q4 2024, and up 4.25% on a QoQ basis from $92.8 million in Q3 2025.
Autolus Therapeutics (AUTL) Operating Expenses (2017 - 2026) Analysis & Trends
Autolus Therapeutics (AUTL) has 9 years of Operating Expenses data on file, last reported at $96.8 million in Q4 2025.
- Quarterly Operating Expenses rose 27.49% year-over-year to $96.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $345.9 million (up 37.52% YoY) and the FY2025 annual result came in at $345.9 million, up 37.52% from the prior year.
- Operating Expenses rose to $96.8 million in Q4 2025, from $92.8 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $96.8 million in Q4 2025 to a low of $15.0 million in Q4 2022.
- A 5-year average of $52.4 million and a median of $43.6 million in 2023 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2021 — Operating Expenses sank 51.24% — and 2023, when it jumped 256.09%.
- Tracing AUTL's Operating Expenses over 5 years: stood at $23.3 million in 2021, then tumbled by 35.73% to $15.0 million in 2022, then jumped by 256.09% to $53.3 million in 2023, then jumped by 42.47% to $75.9 million in 2024, then grew by 27.49% to $96.8 million in 2025.
- The last three Operating Expenses figures came in at $96.8 million (Q4 2025), $92.8 million (Q3 2025), and $82.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Autolus Therapeutics | 763.37 Mn | 561.74 Mn | 25.22 Mn | 89.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 89.53 Mn |
| Dec 31, 2025 | 96.76 Mn |
| Sep 30, 2025 | 92.82 Mn |
| Jun 30, 2025 | 82.14 Mn |
| Mar 31, 2025 | 74.22 Mn |
| Dec 31, 2024 | 75.89 Mn |
| Sep 30, 2024 | 67.88 Mn |
| Jun 30, 2024 | 58.93 Mn |
| Mar 31, 2024 | 48.85 Mn |
| Dec 31, 2023 | 53.27 Mn |
| Sep 30, 2023 | 42.93 Mn |
| Jun 30, 2023 | 44.35 Mn |
| Mar 31, 2023 | 36.67 Mn |
| Dec 31, 2022 | 14.96 Mn |
| Sep 30, 2022 | 39.72 Mn |
| Jun 30, 2022 | 39.06 Mn |
| Mar 31, 2022 | 36.35 Mn |
| Dec 31, 2021 | 23.28 Mn |
| Sep 30, 2021 | 40.59 Mn |
| Jun 30, 2021 | 39.37 Mn |